文献速递创伤与烧伤重症综合管理与镇静镇痛

NRF2与mTOR抑制多模式治疗在烧伤合并吸入性损伤后重编程急性全身与肺部免疫反应

MULTIMODAL NUCLEAR FACTOR-ERYTHROID-2-RELATED FACTOR (NRF2) THERAPY IN THE CONTEXT OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITION REPROGRAMS THE ACUTE SYSTEMIC AND PULMONARY IMMUNE RESPONSE AFTER COMBINED BURN AND INHALATION INJURY.
PubMed 文献 · Shock · 2024-08-21
一句话结论小鼠烧伤合并吸入性损伤模型中,伤后1小时给予CDDO与雷帕霉素PLGA微粒可降低肺部细菌负荷并重编程免疫反应。

该研究在烧伤合并吸入性损伤(B+I)小鼠模型中,将生物相容性NRF2激动剂CDDO与雷帕霉素(RAPA)制成PLGA微粒(MP),伤后1小时给予CDDO-MP或CDDO-MP联合RAPA-MP(Combo-MP)。伤后48小时,Combo-MP组肺部及全身免疫基因激活模式显著改变,炎症基因表达较未治疗组或CDDO-MP组显著降低。伤后1小时给予Combo-MP、48小时后接种铜绿假单胞菌(PAO1)的小鼠,感染后48小时肺和肝脏细菌计数较未治疗B+I小鼠显著减少,并伴随肺和血浆细胞因子谱改变及肺、脾细胞免疫重编程。作者认为多模式MP治疗在重编程烧伤后免疫反应、减轻高炎症期和预防后续感染易感性方面具有前景。

要点

  • 烧伤合并吸入性损伤小鼠伤后1小时给予Combo-MP,伤后48小时炎症基因表达较未治疗或CDDO-MP治疗小鼠显著降低。
  • B+I小鼠伤后1小时给予Combo-MP、48小时后接种铜绿假单胞菌(PAO1),感染后48小时肺和肝脏细菌计数较未治疗B+I小鼠显著减少。
  • 细菌计数减少伴随肺和血浆细胞因子谱显著改变及肺、脾细胞免疫重编程。
  • CDDO-MP或Combo-MP在伤后1小时给药可改变肺和全身免疫基因及其相关免疫通路的激活模式。
  • 作者认为基于MP的多模式治疗在重编程烧伤后免疫反应方面具有前景,尤其可减轻高炎症期并预防后续感染易感性。

适用人群与场景

  • 小鼠烧伤合并吸入性损伤(B+I)模型。

处置流程与药物剂量

  • 伤后1小时给予CDDO-MP或CDDO-MP联合RAPA-MP(Combo-MP)。
  • 伤后1小时给予Combo-MP,48小时后接种铜绿假单胞菌(PAO1),感染后48小时评估。

研究设计与关键结果

  • 研究类型:小鼠烧伤合并吸入性损伤模型实验。
  • 干预与对照:伤后1小时给予CDDO-MP或Combo-MP(CDDO-MP联合RAPA-MP),对照为未治疗或CDDO-MP治疗。
  • 主要终点:伤后48小时肺和全身免疫基因激活模式显著改变,Combo-MP组炎症基因表达较未治疗组或CDDO-MP组显著降低。
  • 感染终点:伤后1小时给予Combo-MP、48小时后接种PAO1、感染后48小时,肺和肝脏细菌计数较未治疗B+I小鼠显著减少。
  • 次要终点:细菌计数减少伴随肺和血浆细胞因子谱显著改变及肺、脾细胞免疫重编程。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Severe burn injuries induce acute and chronic susceptibility to infections, which is largely attributed to a hyper-proinflammatory response followed by a chronic anti-inflammatory response. Concurrent inhalation injury (B + I) causes airway inflammation. Pulmonary macrophages and neutrophils are "hyperactive" with increased reactive oxygen (ROS) and nitrogen species (RONS) activity, but are unable to clear infection, causing airway damage upon activation. Nuclear factor-erythroid-2-related factor (NRF2) is a critical immunomodulatory component that induces compensatory anti-inflammatory pathways when activated. On the other hand, inhibition of mammalian target of rapamycin (mTOR) reduces proinflammatory responses. The therapeutic use of these targets is limited, as known modulators of these pathways are insoluble in saline and require long-term administration. A biocompatible NRF2 agonist (CDDO) and rapamycin (RAPA) poly(lactic-co-glycolic acid) (PLGA) microparticles (MP) were created, which we hypothesized would reduce the acute hyper-inflammatory response in our murine model of B + I injury. BI-injured mice that received CDDO-MP or both CDDO-MP and RAPA-MP (Combo-MP) an hour after injury displayed significant changes in the activation patterns of pulmonary and systemic immune genes and their associated immune pathways 48 h after injury. For example, mice treated with Combo-MP showed a significant reduction in inflammatory gene expression compared to untreated or CDDO-MP-treated mice. We also hypothesized that Combo-MP therapy would acutely decrease bacterial susceptibility after injury. BI-injured mice that received Combo-MP an hour after injury, inoculated 48 h later with Pseudomonas aeruginosa (PAO1), and sacrificed 48 h after infection displayed significantly decreased bacterial counts in the lungs and liver versus untreated B + I mice. This reduction in infection was accompanied by significantly altered lung and plasma cytokine profiles and immune reprogramming of pulmonary and splenic cells. Our findings strongly suggest that multimodal MP-based therapy holds considerable promise for reprogramming the immune response after burn injuries, particularly by mitigating the hyper-inflammatory phase and preventing subsequent susceptibility to infection.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Alves MD, Clark RA, Hernandez DA, et al. MULTIMODAL NUCLEAR FACTOR-ERYTHROID-2-RELATED FACTOR (NRF2) THERAPY IN THE CONTEXT OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITION REPROGRAMS THE ACUTE SYSTEMIC AND PULMONARY IMMUNE RESPONSE AFTER COMBINED BURN AND INHALATION INJURY. Shock. 2024. PMID: 39178221. doi:10.1097/SHK.0000000000002466

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。